Risk factors

Acquisition of Quantum Circuits creates integration costs, execution risks, and uncertainty over annealing and gate-model synergies.

Ralliant Corp faces extensive operational, regulatory, and financial risks as a newly independent public company following its separation from Fortive.

Customer concentration increased, with Verizon generating 17 percent and top five customers accounting for 41 percent of revenue. Supply chain risks now explicitly factor in potential component tariffs and price increases. Artificial intelligence integration introduces new cybersecurity vulnerabilities and financial analysis risks.

Rocket Pharmaceuticals implemented a 30% workforce reduction to cut operating expenses by 25% and extend cash runway.

Net losses narrowed to $41.8 million in 2025, leaving an accumulated deficit of $1.295 billion. Debt balances shifted across 2028, 2029, and 2031 notes, adding repayment burdens. AI governance and global trade tariffs were introduced as distinct operational risks.

FDA staffing reductions and policy changes now threaten clinical trial timelines and product approvals. Nasdaq's proposed $5 million public float rule introduces delisting risks. The company narrowed its focus to GEM-AKI and GEM-CKD, dropping GEM-PSI.

Repligen added new risks regarding joint ventures, ongoing IT and inventory material weaknesses, ESG reporting, and cyber threats. The company updated financial health care disclosures to reference the OBBBA enacted in July 2025.

Rocket Lab added performance-based contract risks and tariff-related supply chain exposure, while noting higher net losses of $198.2 million in 2025.

Relay Therapeutics highlights clinical side effects for combination therapies and new FDA companion diagnostic requirements for zovegalisib. The company expands risks regarding reliance on third-party manufacturers, intellectual property challenges, and cybersecurity compliance under Massachusetts regulations. Regulatory pathways such as RTOR are noted as providing no guarantee of faster approval.

The risk profile is dominated by the acquisition of OmniMax, adding $1.3 billion in debt and heavy integration hurdles.

The company added specific risk disclosures regarding cybersecurity insurance adequacy and variable interest rate exposure on debt. New trade policy changes under the U.S. government were incorporated into foreign metal import risks. Labor union coverage statistics and expiring agreements were updated for 2026.

OBBB shortens the 48E solar credit timeline and adds foreign-entity restrictions that could raise costs or reduce demand.